The New Drug Application (NDA) for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for patients with HIV-1 infection has been submitted to the Food and Drug Administration (FDA).
Activists have been urging Gilead to make the generic drug more widely available.
Truvada is approved in combination with safer sex practices for HIV-1 PrEP to reduce the risk of sexually acquired HIV-1.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Zero rate of HIV transmission seen through condomless sex when viral load is suppressed
Facial involves injecting nutrient-rich plasma into the face using a microneedling pen.
Monotherapy with UB-421 antibody, which blocks the HIV virus-binding site on human CD4+ T-cells, maintains viral suppression for up to 16 weeks in HIV-infected persons undergoing analytic treatment interruption.
Doravirine resistance is uncommon in people with HIV who have been treated with non-nucleoside reverse transcriptase inhibitors.
Significant levels of cytomegalovirus DNA are common in older African children with perinatally acquired HIV infection.
Dovato indicated for use in patients with no history of antiretroviral treatment.
